International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Summary
Third Opinion Trial Synopsis:
This study is for people with a type of cancer called multiple myeloma. It is for people who have been in a previous study using a treatment called isatuximab. The purpose of this study is to see if it is safe to keep using isatuximab for a longer period of time. Adult participants who have finished the previous study can join this new study. The main goal is to see if isatuximab is safe for a long time.
This study is for people with a type of cancer called multiple myeloma. It is for people who have been in a previous study using a treatment called isatuximab. The purpose of this study is to see if it is safe to keep using isatuximab for a longer period of time. Adult participants who have finished the previous study can join this new study. The main goal is to see if isatuximab is safe for a long time.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a multi-center, open-label, Phase 2 treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study. This Treatment Extension study has the purpose to provide continued access to isatuximab. Adult participants with multiple myeloma who have enrolled on an isatuximab parental study for which study objectives are completed will be eligible to be enrolled in this Treatment Extension study. The primary objective of the study is to assess long-term safety of isatuximab as study treatment.
This is a multi-center, open-label, Phase 2 treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study. This Treatment Extension study has the purpose to provide continued access to isatuximab. Adult participants with multiple myeloma who have enrolled on an isatuximab parental study for which study objectives are completed will be eligible to be enrolled in this Treatment Extension study. The primary objective of the study is to assess long-term safety of isatuximab as study treatment.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: